Marker Predicts Outcomes in mCRPC Treated With AR-Targeted Therapy

Video

This video examines the results of a study that looked at the prognostic value of androgen receptor full-length detection using a CTC-based mRNA assay in metastatic castration-resistant prostate cancer patients starting treatment with AR-targeted agents.

In this video, Emmanuel S. Antonarakis, MD, of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, discusses the results of a study that examined the prognostic value of full-length androgen receptor (AR-FL) detection using a circulating tumor cell (CTC)-based mRNA assay.

The researchers studied 202 patients with metastatic castration-resistant prostate cancer (mCRPC) starting treatment with the AR-targeted agents abiraterone or enzalutamide. AR-FL status was negative in 97 patients (48%), less than the median in 52 patients (26%), and greater than the median in 53 patients (26%). In Kaplan-Meier analysis clinical outcomes including progression-free and overall survival were significantly different between the three groups.

The study (abstract 132) was presented at the 2017 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, held February 16–18 in Orlando, Florida.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content